Cargando…

Congenital Cataracts – Facial Dysmorphism – Neuropathy

Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex developmental disorder of autosomal recessive inheritance. To date, CCFDN has been found to occur exclusively in patients of Roma (Gypsy) ethnicity; over 100 patients have been diagnosed. Developmental abnormalities inc...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalaydjieva, Luba
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1563997/
https://www.ncbi.nlm.nih.gov/pubmed/16939648
http://dx.doi.org/10.1186/1750-1172-1-32
_version_ 1782129529434669056
author Kalaydjieva, Luba
author_facet Kalaydjieva, Luba
author_sort Kalaydjieva, Luba
collection PubMed
description Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex developmental disorder of autosomal recessive inheritance. To date, CCFDN has been found to occur exclusively in patients of Roma (Gypsy) ethnicity; over 100 patients have been diagnosed. Developmental abnormalities include congenital cataracts and microcorneae, primary hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, mild facial dysmorphism and hypogonadism. Para-infectious rhabdomyolysis is a serious complication reported in an increasing number of patients. During general anaesthesia, patients with CCFDN require careful monitoring as they have an elevated risk of complications. CCFDN is a genetically homogeneous condition in which all patients are homozygous for the same ancestral mutation in the CTDP1 gene. Diagnosis is clinical and is supported by electrophysiological and brain imaging studies. The major differential diagnosis is Marinesco-Sjögren syndrome. The definitive diagnosis is molecular, based on homozygosity for the CTDP1 mutation. CTDP1 maps to 18qter and encodes a protein phosphatase whose only known substrate is the phosphorylated serine residues of the carboxy-terminal domain of the largest subunit of RNA polymerase II, indicating that CCFDN affects basic cellular processes of gene expression and developmental regulation. Families benefit from genetic counselling and predictive testing. Management includes surgical treatment of the cataracts, and rehabilitation and corrective orthopaedic surgery for the peripheral neuropathy. Thus, the most disabling manifestations, though not curable, are manageable, and allow an acceptable quality of life and everyday living. Current data indicate that patients survive well into adulthood.
format Text
id pubmed-1563997
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15639972006-09-12 Congenital Cataracts – Facial Dysmorphism – Neuropathy Kalaydjieva, Luba Orphanet J Rare Dis Review Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex developmental disorder of autosomal recessive inheritance. To date, CCFDN has been found to occur exclusively in patients of Roma (Gypsy) ethnicity; over 100 patients have been diagnosed. Developmental abnormalities include congenital cataracts and microcorneae, primary hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, mild facial dysmorphism and hypogonadism. Para-infectious rhabdomyolysis is a serious complication reported in an increasing number of patients. During general anaesthesia, patients with CCFDN require careful monitoring as they have an elevated risk of complications. CCFDN is a genetically homogeneous condition in which all patients are homozygous for the same ancestral mutation in the CTDP1 gene. Diagnosis is clinical and is supported by electrophysiological and brain imaging studies. The major differential diagnosis is Marinesco-Sjögren syndrome. The definitive diagnosis is molecular, based on homozygosity for the CTDP1 mutation. CTDP1 maps to 18qter and encodes a protein phosphatase whose only known substrate is the phosphorylated serine residues of the carboxy-terminal domain of the largest subunit of RNA polymerase II, indicating that CCFDN affects basic cellular processes of gene expression and developmental regulation. Families benefit from genetic counselling and predictive testing. Management includes surgical treatment of the cataracts, and rehabilitation and corrective orthopaedic surgery for the peripheral neuropathy. Thus, the most disabling manifestations, though not curable, are manageable, and allow an acceptable quality of life and everyday living. Current data indicate that patients survive well into adulthood. BioMed Central 2006-08-29 /pmc/articles/PMC1563997/ /pubmed/16939648 http://dx.doi.org/10.1186/1750-1172-1-32 Text en Copyright © 2006 Kalaydjieva; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kalaydjieva, Luba
Congenital Cataracts – Facial Dysmorphism – Neuropathy
title Congenital Cataracts – Facial Dysmorphism – Neuropathy
title_full Congenital Cataracts – Facial Dysmorphism – Neuropathy
title_fullStr Congenital Cataracts – Facial Dysmorphism – Neuropathy
title_full_unstemmed Congenital Cataracts – Facial Dysmorphism – Neuropathy
title_short Congenital Cataracts – Facial Dysmorphism – Neuropathy
title_sort congenital cataracts – facial dysmorphism – neuropathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1563997/
https://www.ncbi.nlm.nih.gov/pubmed/16939648
http://dx.doi.org/10.1186/1750-1172-1-32
work_keys_str_mv AT kalaydjievaluba congenitalcataractsfacialdysmorphismneuropathy